n(1),n(11)-diethylnorspermine has been researched along with Adenocarcinoma, Basal Cell in 9 studies
N(1),N(11)-diethylnorspermine: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using three cytotoxicity assays, we have investigated the effect of the spermine analogue N1,N11-diethylnorspermine (DENSPM) on four human breast cancer cell lines with different known genetic lesions." | 7.73 | Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines. ( Holst, CM; Oredsson, SM, 2005) |
| "Using three cytotoxicity assays, we have investigated the effect of the spermine analogue N1,N11-diethylnorspermine (DENSPM) on four human breast cancer cell lines with different known genetic lesions." | 3.73 | Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines. ( Holst, CM; Oredsson, SM, 2005) |
| "This 52-year-old male without a significant medical history was receiving chemotherapy with diethylnorspermine (DENSPM), a polyamine analogue, for a partially resected pancreatic adenocarcinoma." | 3.70 | Chemotherapy for pancreatic cancer: a neuroimaging clinicopathologic correlation. ( Rojiani, AM; Valenstein, EJ; Williams, LS, 1999) |
| "Fifteen patients with advanced solid tumors were entered into a phase I study of DENSPM given by a 1 h i." | 2.68 | Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. ( Berghorn, E; Creaven, PJ; Levine, E; Loewen, G; Meropol, NJ; Pendyala, L; Perez, R; Raghavan, D, 1997) |
| "Treatment of human breast cancer cell lines in culture with these analogues has been shown to decrease cell proliferation and induce programmed cell death." | 2.40 | Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. ( Casero, RA; Davidson, NE; Hahm, HA; McCloskey, DE; Woster, PM, 1999) |
| " In vitro studies indicated that the growth sensitivity of most tumor cell lines to DENSPM was similar, with characteristically flat dose-response curves and IC50s ranging between 0." | 1.29 | Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. ( Atwood, A; Bergeron, RJ; Bernacki, RJ; Oberman, EJ; Porter, CW; Seweryniak, KE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (88.89) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holst, CM | 1 |
| Oredsson, SM | 1 |
| Casero, RA | 2 |
| Gabrielson, EW | 1 |
| Pegg, AE | 1 |
| Creaven, PJ | 1 |
| Perez, R | 1 |
| Pendyala, L | 1 |
| Meropol, NJ | 1 |
| Loewen, G | 1 |
| Levine, E | 1 |
| Berghorn, E | 1 |
| Raghavan, D | 1 |
| Zagaja, GP | 1 |
| Shrivastav, M | 1 |
| Fleig, MJ | 1 |
| Marton, LJ | 1 |
| Rinker-Schaeffer, CW | 1 |
| Dolan, ME | 1 |
| Bernacki, RJ | 1 |
| Oberman, EJ | 1 |
| Seweryniak, KE | 1 |
| Atwood, A | 1 |
| Bergeron, RJ | 3 |
| Porter, CW | 3 |
| Rojiani, AM | 1 |
| Williams, LS | 1 |
| Valenstein, EJ | 1 |
| Davidson, NE | 1 |
| Hahm, HA | 1 |
| McCloskey, DE | 1 |
| Woster, PM | 1 |
| Chang, BK | 2 |
| Liang, Y | 2 |
| Vinson, JR | 1 |
| Libby, PR | 1 |
1 review available for n(1),n(11)-diethylnorspermine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment.
Topics: Acetyltransferases; Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Divisio | 1999 |
1 trial available for n(1),n(11)-diethylnorspermine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Centr | 1997 |
7 other studies available for n(1),n(11)-diethylnorspermine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Comparison of three cytotoxicity tests in the evaluation of the cytotoxicity of a spermine analogue on human breast cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; | 2005 |
Immunohistochemical staining of human spermidine/spermine N1-acetyltransferase superinduced in response to treatment with antitumor polyamine analogues.
Topics: Acetyltransferases; Adenocarcinoma; Animals; Antibodies; Antineoplastic Agents; Drug Screening Assay | 1994 |
Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Dose-Response Relationship | 1998 |
Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Drug Administratio | 1995 |
Chemotherapy for pancreatic cancer: a neuroimaging clinicopathologic correlation.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain; Brain Neoplasms; Demyelinating Diseases; Diagnosis, Di | 1999 |
Antitumor effects of N-alkylated polyamine analogues in human pancreatic adenocarcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Humans; Male; Mice; Mice, Nude; Neoplasm Transplanta | 1992 |
Regulatory and antiproliferative effects of N-alkylated polyamine analogues in human and hamster pancreatic adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Humans; Mesocricetus; Pancreatic Neoplas | 1992 |